Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model
Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation...
Uložené v:
| Vydané v: | Clinical and experimental immunology Ročník 163; číslo 3; s. 375 - 380 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Oxford, UK
Blackwell Publishing Ltd
01.03.2011
Blackwell Oxford University Press Blackwell Science Inc |
| Predmet: | |
| ISSN: | 0009-9104, 1365-2249, 1365-2249 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. RIP-LCMV-glycoprotein (GP) mice were treated after new-onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new-onset T1D in this model. The CD4 : CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG-treated mice. Although the percentage of CD4⁺CD25⁺ regulatory T cells (Tregs) within the CD4⁺ population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP-LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4⁺CD25⁺ Tregs frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials. |
|---|---|
| AbstractList | Summary
Immune modulators such as anti‐thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non‐obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter‐lymphocytic choriomeningitis virus (RIP‐LCMV) model. RIP‐LCMV‐glycoprotein (GP) mice were treated after new‐onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new‐onset T1D in this model. The CD4 : CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG‐treated mice. Although the percentage of CD4+CD25+ regulatory T cells (Tregs) within the CD4+ population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP‐LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4+CD25+ Tregs frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune‐based interventions and select the most potent therapies for future clinical trials. Summary Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. RIP-LCMV-glycoprotein (GP) mice were treated after new-onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new-onset T1D in this model. The CD4 : CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG-treated mice. Although the percentage of CD4+CD25+ regulatory T cells (Tregs) within the CD4+ population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP-LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4+CD25+ Tregs frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials. [PUBLICATION ABSTRACT] Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. RIP-LCMV-glycoprotein (GP) mice were treated after new-onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new-onset T1D in this model. The CD4 : CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG-treated mice. Although the percentage of CD4⁺CD25⁺ regulatory T cells (Tregs) within the CD4⁺ population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP-LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4⁺CD25⁺ Tregs frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials. Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. RIP-LCMV-glycoprotein (GP) mice were treated after new-onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new-onset T1D in this model. The CD4:CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG-treated mice. Although the percentage of CD4(+) CD25(+) regulatory T cells (T(regs) ) within the CD4(+) population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP-LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4(+) CD25(+) T(regs) frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials.Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. RIP-LCMV-glycoprotein (GP) mice were treated after new-onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new-onset T1D in this model. The CD4:CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG-treated mice. Although the percentage of CD4(+) CD25(+) regulatory T cells (T(regs) ) within the CD4(+) population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP-LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4(+) CD25(+) T(regs) frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials. Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. RIP-LCMV-glycoprotein (GP) mice were treated after new-onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new-onset T1D in this model. The CD4:CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG-treated mice. Although the percentage of CD4(+) CD25(+) regulatory T cells (T(regs) ) within the CD4(+) population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP-LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4(+) CD25(+) T(regs) frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials. Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured T1D in the non-obese diabetic (NOD) model, their clinical efficacy has been much lower. In order to improve the odds of successful translation from bench to bedside, we propose to evaluate this agent under more stringent conditions. Here, we evaluated the capacity of ATG to reverse T1D in the acute rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. RIP-LCMV-glycoprotein (GP) mice were treated after new-onset T1D with murine ATG antibodies. Although ATG treatment did not impair viral clearance it failed to reverse new-onset T1D in this model. The CD4 : CD8 ratio was reduced drastically upon LCMV infection due to an expansion of CD8 effectors but ameliorated in ATG-treated mice. Although the percentage of CD4+CD25+ regulatory T cells (Tregs) within the CD4+ population was increased significantly after ATG therapy, their frequency in the periphery was reduced dramatically and never returned to normal baseline. The inability of ATG treatment to cure T1D in a stringent viral model (RIP-LCMV mice) is due at least partially to the inability to maintain or increase a sufficient CD4+CD25+ Tregs frequency, in striking contrast with what was reported in the NOD model. Our data would argue for the use of multiple animal models to assess efficacy of promising immune-based interventions and select the most potent therapies for future clinical trials. |
| Author | Bresson, D von Herrath, M.G |
| Author_xml | – sequence: 1 fullname: Bresson, D – sequence: 2 fullname: von Herrath, M.G |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23864344$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21235534$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks1u1DAUhSNURH_gFcASQrSLDP5PsgBpNCqlUhEIWraWYzszHiXxYDuleSTeEqdTpsCGZhPb97vH9vE5zPZ615ssAwjOUPrerGeIcJZjTKsZhmkVUgLp7OZRdrAr7GUHEMIqrxCk-9lhCOs05ZzjJ9k-RpgwRuhB9nPeR5vH1di5ZevqobU9OJ5fnp2A6I2Mnekj0M4E0LsIvLk2PhgQx40BCGgraxNTLfXElQFSDdGAa-tl245pUQ_KaOBlTONwq7zxrnPR-Lwdu83KqTFaBdTKeevSTrZf2mjDpDAEcPzl_HN-sfj47QR0Tpv2afa4kW0wz-7-R9nV-9PLxYf84tPZ-WJ-kStWFjQnNUe0aupSN4VWda1rzAuktWFFKZMVmJclqiFkDFYa1w3lhlWVRopIXHFDyFH2bqu7GerOaJUcSBcSG2876UfhpBV_V3q7Ekt3LdILlBzjJPD6TsC774MJUXQ2KNO2sjduCKIsKloQyIr_kwxhzDmpEvnyH3LtBt8nHwRiuGKEFZgm6vmfR9-d-fdzJ-DVHSCDkm3jZa9suOdIySmhE1duOeVdCN40OwRBMSVQrMUUNDEFTUwJFLcJFDf39u1alY0yWjeZZduHCLzdCvywrRkfvLFYnJ5Po9T_YtvfSCfk0qf7XX1NJIGoooggSn4BToH_gg |
| CODEN | CEXIAL |
| CitedBy_id | crossref_primary_10_1016_j_transproceed_2011_09_057 crossref_primary_10_2217_dmt_12_3 crossref_primary_10_3109_08830185_2015_1010723 crossref_primary_10_1038_nrd3402 crossref_primary_10_1016_j_jaut_2011_10_001 crossref_primary_10_1016_j_mehy_2013_03_046 crossref_primary_10_1097_BOR_0b013e3283556515 crossref_primary_10_1111_cei_12085 |
| Cites_doi | 10.4049/jimmunol.165.10.5945 10.1111/j.1600-6143.2008.02404.x 10.2337/db06-1384 10.2337/db09-0160 10.1073/pnas.89.8.3434 10.1016/j.jaut.2006.03.001 10.1146/annurev.immunol.23.021704.115643 10.1016/j.autrev.2006.09.013 10.1016/1074-7613(94)90101-5 10.1016/j.immuni.2005.08.002 10.1073/pnas.91.1.123 10.1016/j.jviromet.2007.08.025 10.4049/jimmunol.168.2.933 10.1038/nri1502 |
| ContentType | Journal Article |
| Copyright | 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology 2015 INIST-CNRS 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology. Copyright © 2011 British Society for Immunology |
| Copyright_xml | – notice: 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology – notice: 2015 INIST-CNRS – notice: 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology. – notice: Copyright © 2011 British Society for Immunology |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 M7N 7X8 5PM |
| DOI | 10.1111/j.1365-2249.2010.04304.x |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1365-2249 |
| EndPage | 380 |
| ExternalDocumentID | PMC3048622 3317456151 21235534 23864344 10_1111_j_1365_2249_2010_04304_x CEI4304 US201301941314 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 169 1OC 24P 29B 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 5WD 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AABZA AACZT AAESR AAEVG AAHHS AAONW AAPXW AAVAP AAVGM AAZKR ABCQN ABCUV ABDBF ABEML ABHUG ABJNI ABLJU ABOCM ABPTD ABPTK ABPVW ABWRO ACAHQ ACCFJ ACFBH ACGFO ACGFS ACMXC ACPOU ACPRK ACSCC ACUFI ACXME ACXQS ADAWD ADBBV ADDAD ADEOM ADIPN ADIYS ADIZJ ADKYN ADMGS ADOZA ADVEK ADXAS ADZOD AEEZP AEGXH AEIMD AENEX AEQDE AEQTP AEUQT AFBPY AFEBI AFFZL AFGKR AFPWT AFRAH AFVGU AFXAL AFZJQ AGJLS AGUTN AIACR AIAGR AIURR AIWBW AJAOE AJBDE AJEEA ALAGY ALMA_UNASSIGNED_HOLDINGS ALXQX AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BCRHZ BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EAD EAP EAS EBB EBC EBD EBS EBX EJD EMB EMK EMOBN ESTFP ESX EX3 F00 F01 F04 F5P FBQ FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HZI HZ~ IH2 IHE IPNFZ IX1 J0M J5H K48 KBUDW KBYEO KOP KSI KSN LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NOMLY O66 O9- OAUYM OBS OCZFY OHT OJZSN OK1 OPAEJ OVD OWPYF P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 Q~Q R.K ROL ROX RPM RX1 SUPJJ SV3 TEORI TR2 TUS UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOQ WOW WQJ WRC WVDHM WXI X7M XG1 Y6R YFH YOC YUY ZA5 ZGI ZXP ZZTAW ~IA ~KM ~WT AAFWJ AAMMB AARHZ AAUAY ABDFA ABEJV ABGNP ABNHQ ABQNK ABVGC ABXVV ACUHS ACVCV ADQBN ADZMN AEFGJ AEMQT AFFQV AFTUV AGMDO AGXDD AHGBF AHMMS AIDQK AIDYY AJBYB AJDVS AJNCP ATGXG BEYMZ H13 NU- OIG AAYXX CITATION O8X AGORE IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 M7N 7X8 5PM |
| ID | FETCH-LOGICAL-c5874-3b6149fb8df7dcbbdb2671dde578a10426881b005509d2bf46e599d1c3a296e33 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 9 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000287091900013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0009-9104 1365-2249 |
| IngestDate | Tue Sep 30 16:54:34 EDT 2025 Sun Sep 28 09:20:26 EDT 2025 Thu Oct 02 06:53:28 EDT 2025 Wed Aug 13 06:53:58 EDT 2025 Mon Jul 21 05:45:59 EDT 2025 Mon Jul 21 09:17:55 EDT 2025 Sat Nov 29 06:02:00 EST 2025 Tue Nov 18 22:31:45 EST 2025 Sun Sep 21 06:15:21 EDT 2025 Wed Dec 27 19:21:35 EST 2023 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Endocrinopathy Autoimmunity Pancreatic hormone Rat Autoimmune disease Biochemistry Promoter T-Lymphocyte anti-thymoglobulin Antithymocyte globulin Regulatory cell RIP-LCMV mice Immunopathology Acute Rodentia Insulin Arenavirus Virus regulatory T cells Vertebrata Mammalia Treatment Lymphocytic choriomeningitis virus Mouse Type 1 diabetes Animal Reversibility Models Arenaviridae |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model CC BY 4.0 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5874-3b6149fb8df7dcbbdb2671dde578a10426881b005509d2bf46e599d1c3a296e33 |
| Notes | http://dx.doi.org/10.1111/j.1365-2249.2010.04304.x ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://academic.oup.com/cei/article-pdf/163/3/375/41909418/j.1365-2249.2010.04304.x.pdf |
| PMID | 21235534 |
| PQID | 1529535724 |
| PQPubID | 36527 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3048622 proquest_miscellaneous_879473057 proquest_miscellaneous_851226639 proquest_journals_1529535724 pubmed_primary_21235534 pascalfrancis_primary_23864344 crossref_primary_10_1111_j_1365_2249_2010_04304_x crossref_citationtrail_10_1111_j_1365_2249_2010_04304_x wiley_primary_10_1111_j_1365_2249_2010_04304_x_CEI4304 fao_agris_US201301941314 |
| PublicationCentury | 2000 |
| PublicationDate | March 2011 |
| PublicationDateYYYYMMDD | 2011-03-01 |
| PublicationDate_xml | – month: 03 year: 2011 text: March 2011 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | Clinical and experimental immunology |
| PublicationTitleAlternate | Clin Exp Immunol |
| PublicationYear | 2011 |
| Publisher | Blackwell Publishing Ltd Blackwell Oxford University Press Blackwell Science Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell – name: Oxford University Press – name: Blackwell Science Inc |
| References | 2009; 58 1985; 2 2002; 168 2006; 26 2004; 4 2007; 6 2008; 57 2008; 8 2000; 165 2008; 147 1994; 1 1994; 91 1992; 89 2005; 23 Roep (2021122708482645200_b2) 2004; 4 Bresson (2021122708482645200_b8) 2007; 6 Shoda (2021122708482645200_b1) 2005; 23 Simon (2021122708482645200_b5) 2008; 57 Holz (2021122708482645200_b7) 2000; 165 Anderson (2021122708482645200_b15) 2005; 23 Maki (2021122708482645200_b10) 1992; 89 von Herrath (2021122708482645200_b3) 1994; 1 Hilbrands (2021122708482645200_b14) 2009; 58 von Herrath (2021122708482645200_b4) 2002; 168 Bellin (2021122708482645200_b13) 2008; 8 Eisenbarth (2021122708482645200_b12) 1985; 2 Chatenoud (2021122708482645200_b9) 1994; 91 Ogawa (2021122708482645200_b11) 2006; 26 McCausland (2021122708482645200_b6) 2008; 147 7889411 - Immunity. 1994 Jun;1(3):231-42 8278351 - Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):123-7 15573133 - Nat Rev Immunol. 2004 Dec;4(12):989-97 17920702 - J Virol Methods. 2008 Jan;147(1):167-76 19602536 - Diabetes. 2009 Oct;58(10):2267-76 11067957 - J Immunol. 2000 Nov 15;165(10):5945-53 1565635 - Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3434-8 15771578 - Annu Rev Immunol. 2005;23:447-85 17412305 - Autoimmun Rev. 2007 Apr;6(5):315-22 16713179 - J Autoimmun. 2006 Jun;26(4):225-31 18808408 - Am J Transplant. 2008 Nov;8(11):2463-70 18039815 - Diabetes. 2008 Feb;57(2):405-14 11777992 - J Immunol. 2002 Jan 15;168(2):933-41 16111631 - Immunity. 2005 Aug;23(2):115-26 3878262 - Diabetes Res. 1985 Nov;2(6):271-6 |
| References_xml | – volume: 2 start-page: 271 year: 1985 end-page: 6 article-title: Anti‐thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus publication-title: Diabetes Res – volume: 168 start-page: 933 year: 2002 end-page: 41 article-title: Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter‐lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance publication-title: J Immunol – volume: 26 start-page: 225 year: 2006 end-page: 31 article-title: Short administration of polyclonal anti‐T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes publication-title: J Autoimmun – volume: 4 start-page: 989 year: 2004 end-page: 97 article-title: Satisfaction (not) guaranteed: re‐evaluating the use of animal models of type 1 diabetes publication-title: Nat Rev Immunol – volume: 165 start-page: 5945 year: 2000 end-page: 53 article-title: Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus‐induced autoimmune diabetes publication-title: J Immunol – volume: 23 start-page: 447 year: 2005 end-page: 85 article-title: The NOD mouse: a model of immune dysregulation publication-title: Annu Rev Immunol – volume: 89 start-page: 3434 year: 1992 end-page: 8 article-title: Long‐term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti‐lymphocyte serum publication-title: Proc Natl Acad Sci USA – volume: 1 start-page: 231 year: 1994 end-page: 42 article-title: How virus induces a rapid or slow onset insulin‐dependent diabetes mellitus in a transgenic model publication-title: Immunity – volume: 58 start-page: 2267 year: 2009 end-page: 76 article-title: Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients publication-title: Diabetes – volume: 147 start-page: 167 year: 2008 end-page: 76 article-title: Quantitative PCR technique for detecting lymphocytic choriomeningitis virus publication-title: J Virol Methods – volume: 8 start-page: 2463 year: 2008 end-page: 70 article-title: Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes publication-title: Am J Transplant – volume: 91 start-page: 123 year: 1994 end-page: 7 article-title: CD3 antibody induces long‐term remission of overt autoimmunity in nonobese diabetic mice publication-title: Proc Natl Acad Sci USA – volume: 6 start-page: 315 year: 2007 end-page: 22 article-title: Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? publication-title: Autoimmun Rev – volume: 23 start-page: 115 year: 2005 end-page: 26 article-title: A comprehensive review of interventions in the NOD mouse and implications for translation publication-title: Immunity – volume: 57 start-page: 405 year: 2008 end-page: 14 article-title: Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time‐dependent induction of immunoregulation publication-title: Diabetes – volume: 165 start-page: 5945 year: 2000 ident: 2021122708482645200_b7 article-title: Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes publication-title: J Immunol doi: 10.4049/jimmunol.165.10.5945 – volume: 8 start-page: 2463 year: 2008 ident: 2021122708482645200_b13 article-title: Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2008.02404.x – volume: 57 start-page: 405 year: 2008 ident: 2021122708482645200_b5 article-title: Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation publication-title: Diabetes doi: 10.2337/db06-1384 – volume: 58 start-page: 2267 year: 2009 ident: 2021122708482645200_b14 article-title: Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients publication-title: Diabetes doi: 10.2337/db09-0160 – volume: 89 start-page: 3434 year: 1992 ident: 2021122708482645200_b10 article-title: Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.89.8.3434 – volume: 2 start-page: 271 year: 1985 ident: 2021122708482645200_b12 article-title: Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus publication-title: Diabetes Res – volume: 26 start-page: 225 year: 2006 ident: 2021122708482645200_b11 article-title: Short administration of polyclonal anti-T cell antibody (ALS) in NOD mice with extensive insulitis prevents subsequent development of autoimmune diabetes publication-title: J Autoimmun doi: 10.1016/j.jaut.2006.03.001 – volume: 23 start-page: 447 year: 2005 ident: 2021122708482645200_b15 article-title: The NOD mouse: a model of immune dysregulation publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.23.021704.115643 – volume: 6 start-page: 315 year: 2007 ident: 2021122708482645200_b8 article-title: Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2006.09.013 – volume: 1 start-page: 231 year: 1994 ident: 2021122708482645200_b3 article-title: How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model publication-title: Immunity doi: 10.1016/1074-7613(94)90101-5 – volume: 23 start-page: 115 year: 2005 ident: 2021122708482645200_b1 article-title: A comprehensive review of interventions in the NOD mouse and implications for translation publication-title: Immunity doi: 10.1016/j.immuni.2005.08.002 – volume: 91 start-page: 123 year: 1994 ident: 2021122708482645200_b9 article-title: CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.91.1.123 – volume: 147 start-page: 167 year: 2008 ident: 2021122708482645200_b6 article-title: Quantitative PCR technique for detecting lymphocytic choriomeningitis virus in vivo publication-title: J Virol Methods doi: 10.1016/j.jviromet.2007.08.025 – volume: 168 start-page: 933 year: 2002 ident: 2021122708482645200_b4 article-title: Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance publication-title: J Immunol doi: 10.4049/jimmunol.168.2.933 – volume: 4 start-page: 989 year: 2004 ident: 2021122708482645200_b2 article-title: Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes publication-title: Nat Rev Immunol doi: 10.1038/nri1502 – reference: 15771578 - Annu Rev Immunol. 2005;23:447-85 – reference: 18808408 - Am J Transplant. 2008 Nov;8(11):2463-70 – reference: 17920702 - J Virol Methods. 2008 Jan;147(1):167-76 – reference: 11067957 - J Immunol. 2000 Nov 15;165(10):5945-53 – reference: 15573133 - Nat Rev Immunol. 2004 Dec;4(12):989-97 – reference: 8278351 - Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):123-7 – reference: 11777992 - J Immunol. 2002 Jan 15;168(2):933-41 – reference: 3878262 - Diabetes Res. 1985 Nov;2(6):271-6 – reference: 16713179 - J Autoimmun. 2006 Jun;26(4):225-31 – reference: 17412305 - Autoimmun Rev. 2007 Apr;6(5):315-22 – reference: 16111631 - Immunity. 2005 Aug;23(2):115-26 – reference: 18039815 - Diabetes. 2008 Feb;57(2):405-14 – reference: 19602536 - Diabetes. 2009 Oct;58(10):2267-76 – reference: 1565635 - Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3434-8 – reference: 7889411 - Immunity. 1994 Jun;1(3):231-42 |
| SSID | ssj0006662 |
| Score | 2.0140135 |
| Snippet | Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have cured... Summary Immune modulators such as anti‐thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have... Summary Immune modulators such as anti-thymoglobulin (ATG) are under clinical evaluation for the treatment of type 1 diabetes (T1D). Although such agents have... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wiley fao |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 375 |
| SubjectTerms | Analytical, structural and metabolic biochemistry Animal Models Animals Antibodies Antilymphocyte Serum - administration & dosage Antilymphocyte Serum - therapeutic use anti‐thymoglobulin autoimmunity Biological and medical sciences Blood Glucose - metabolism CD25 antigen CD4 antigen CD4-CD8 Ratio CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - pathology CD8 antigen CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - pathology Clinical trials Data processing Diabetes Diabetes mellitus Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - etiology Diabetes Mellitus, Type 1 - immunology Diabetes Mellitus, Type 1 - therapy Diabetes. Impaired glucose tolerance Disease Models, Animal Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Fundamental and applied biological sciences. Psychology Immunomodulation Immunoregulation Infection Insulin Insulin - genetics Interleukin-2 Receptor alpha Subunit - metabolism Kinetics Lymphocyte Count Lymphocyte Depletion Lymphocytes T Lymphocytic choriomeningitis virus - genetics Lymphocytic choriomeningitis virus - isolation & purification Medical research Medical sciences Mice Mice, Inbred C57BL Mice, Transgenic Promoter Regions, Genetic - genetics Rats regulatory T cells RIP‐LCMV mice T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism T-Lymphocyte Subsets - pathology T-Lymphocytes, Regulatory - immunology T-Lymphocytes, Regulatory - metabolism T-Lymphocytes, Regulatory - pathology Translation Treatment Outcome type 1 diabetes Viral Load - immunology |
| Title | Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2249.2010.04304.x https://www.ncbi.nlm.nih.gov/pubmed/21235534 https://www.proquest.com/docview/1529535724 https://www.proquest.com/docview/851226639 https://www.proquest.com/docview/879473057 https://pubmed.ncbi.nlm.nih.gov/PMC3048622 |
| Volume | 163 |
| WOSCitedRecordID | wos000287091900013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1365-2249 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006662 issn: 0009-9104 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1365-2249 dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0006662 issn: 0009-9104 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbYBhMvXMZlhVH5gYftIahxLo4fq7JCpa6axjr6ZtmJDZW6ZEpaRN_4CfwT_hO_hHOSNCxiQhPira0vSeMvx9-xP59DyOtER8xq3GENdOSA_yUcHdvAESpkvbBnuC5TJ1yM-WQSzWbitNY_4VmYKj5Es-CGb0Zpr_EFV7pov-SlQgv8h1qh5YNr_gb45A6esQJHbOft2XA6buwyEHW2yasGk6Tf1vXc2FdrstqyKkPppCrg6dkq7cVNvPRPeeV12lvOW8OH__MfPyIPavZK-xXcHpM7Jt0j96p8lus9sntS79Q_IT_66XL-89t3wMFlhlFHUPFOD_vn745oI26nSWYKmmZLioGk8sJQXBGmLt2sCFNoAwyVqni1NBT1yIvFGn5MAJAJBfDSWktPr0pZocnhkos1IDSL13CPFIx7jgEGqrxM8wL7WBX08Gx0CjXHg5OLI1omA3pKpsPj88F7p04O4cRBxH3H00AshNVRYnkSa51oFnIXjDWYIOWiZxgBI8cQYz2RMG390ARCJG7sKSZC43nPyHaapWaf0NgIE6I1iyLrC22UDpUbq56nrRWeF3YI36BAxnXkdEzgsZDXPCgYGYkjI3FkZDky8muHuE3Lqyp6yC3a7APQpPoERl5OPzDcWnYFcA3X75BuC31Nn8C7gFn6UOFgA0dZ26JCuriX6wWcQTFtisGK4NaQSk22KiTwbuDhwFb_UgUsN0wHAe-Q5xW-f18eD1wHHvTPW8hvKmAM83ZJOv9cxjL3MOQjYx0Slsi_9VOSg-MRfnrxrw1fkvvV9gDKCQ_I9jJfmVfkbvwFsJh3yRafRd3agsC3j6PJLx00cR4 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwFLagg8ENP2OwwBi-4GK7CGri_PmyKiuraKtptNPuLDuxoVJJpqRF9I5H4E14J56Ec5I0LGJCE-Iuin_Sxp8_f_Y5OYeQ14mKXKPQwuqryIb9F7dVbHyby8DtBl0dqjJ1wvkonEyiiwt-WqcDwm9hqvgQzYEbzoySr3GC44F0e5aXLlqwgahdtDzYm78BQbnlBSyMOmTr7dlgNmqIGZS6u0msBquk13bsubav1mp128gMfSdlAa_PVHkvrhOmf_pXXtW95cI1ePhf__Ij8qDWr7RXAe4xuaXTHXK3ymi53iHb49pW_4T86KXL-c9v3wEJnzOMO4I-7_SwN313RBv3dppkuqBptqQYSiovNMUzYerQzZkwhTagUamMV0tN0SN5sVjDzQQgmVCAL6296ell6Vioc3jkYg0YzeI1_EYK9J5jiIEqM9O8wD5WBT08G55CzVF_fH5Ey3RAu2Q2OJ72T-w6PYQd-1Ho2UyBtOBGRYkJk1ipRLlB6ABdAwlJB_eGEWhyDDLW5YmrjBdon_PEiZl0eaAZe0o6aZbqPUJjzXWAfBZFxuNKSxVIJ5ZdpozhjAUWCTcwEHEdOx1TeCzElT0UjIzAkRE4MqIcGfHVIk7T8rKKH3KDNnuANCE_As2L2QcXjcsOB7XheBY5aMGv6ROUF2hLDyrsb_AoajYqhIPWXOaHLhTTphh4BI1DMtXZqhCgvEGJg179SxXgblgQ_NAizyqA_348fnLtM-g_bEG_qYBRzNsl6fxTGc2cYdBH17VIUEL_xm9J9I-HePX8Xxu-IvdOpuORGA0n71-Q-5WxAJ0L90lnma_0S3In_gK4zA9qIvkFwYZzFw |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZgwMQLl3FZYAw_8LA9BDXO1Y9VWaGiqyrYxt4s27GhUkmqpEX0jZ_AP-E_8Us4J0nDIiY0Id6i-JI2_nz82efLOYS8SFXCrEIPa6gSF_Zf3FXahi6XEetFPROrKnXC2TieTJLzcz5t0gHhtzB1fIj2wA1nRmWvcYKbRWq7s7ySaMEGopFoBbA3fwmE8kYAtBz1XR9Gk9YsA09nm7RqsEYGXVnPpT111qrrVuaonJQlvDxbZ724jJb-qa68yHqrZWt497_-4XvkTsNeab-G231yzWQ75Fadz3K9Q7aPG0_9A_Kjny1nP799Bxx8zjHqCCre6UH_5PUhbcXtNM1NSbN8STGQVFEaiifC1KObE2EKbYChUqlXS0NRjzyfr-FmCoBMKYCXNlp6uqhkhaaAR87XgNBcr-E3UjDuBQYYqPMyzUrsY1XSg3ejKdQcD47PDmmVDOghOR0enQzeuE1yCFeHSRy4vgJiwa1KUhunWqlUsSj2wFiDCZIe7gwTYOQYYqzHU6ZsEJmQ89TTvmQ8Mr7_iGxleWZ2CdWGmwitWZLYgCsjVSQ9LXu-spb7fuSQeAMDoZvI6ZjAYy4u7KBgZASOjMCREdXIiK8O8dqWizp6yBXa7ALShPwIRl6cvmfoWvY4cA0vcMh-B35tn8C7gFkGUGFvg0fR2KJSeOjL9cOYQTFti8GKoGtIZiZflQJ4N_BwYKt_qQKWG5aDMHbI4xrgvx-PH1yHPvQfd6DfVsAY5t2SbPapimXuY8hHxhwSVdC_8lsSg6MRXj3514bPyfb01VCMR5O3T8nt2lOAysI9srUsVuYZuam_ACyL_cqK_AL7fnFt |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-thymoglobulin+%28ATG%29+treatment+does+not+reverse+type+1+diabetes+in+the+acute+virally+induced+rat+insulin+promoter-lymphocytic+choriomeningitis+virus+%28RIP-LCMV%29+model&rft.jtitle=Clinical+and+experimental+immunology&rft.au=Bresson%2C+D&rft.au=von+Herrath%2C+M+G&rft.date=2011-03-01&rft.eissn=1365-2249&rft.volume=163&rft.issue=3&rft.spage=375&rft_id=info:doi/10.1111%2Fj.1365-2249.2010.04304.x&rft_id=info%3Apmid%2F21235534&rft.externalDocID=21235534 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9104&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9104&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9104&client=summon |